Status:
UNKNOWN
Total Neoadjuvant Therapy in Rectal Cancer Treatment
Lead Sponsor:
State Scientific Centre of Coloproctology, Russian Federation
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.
Detailed Description
In this randomized, controlled, parallel study we will comparison total neoadjuvant therapy with standard neoadjuvant therapy in rectal cancer treatment. Complete pathological response rate will be th...
Eligibility Criteria
Inclusion
- Have signed an approved informed consent form for the stud;
- Histologically confirmed rectal adenocarcinoma low (cT2-4N0-2M0) or mid rectum (сТ2-T4N1-2M0);
Exclusion
- rectal cancer recurrence;
- Primary-multiple tumours of other localizations;
- pelvis radiotherapy in anamnesis;
- pregnancy, breastfeeding;
- distant metastasis;
- ECOG score 3-4
Key Trial Info
Start Date :
October 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2023
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT04747951
Start Date
October 30 2020
End Date
November 1 2023
Last Update
February 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
State Scientific Centre of Coloproctology
Moscow, Russia, 123453